Cancer almost killed me. We’re treating this disease all wrong
Cancer specialist Karl Smith-Byrne has devoted his career to tackling the disease that could have killed him. He says the way investors, pharmaceutical companies and the government look at the cancer time bomb is all wrong.
In my opinion, Smith-Byrne's personal story is a powerful reminder of the impact of cancer and the urgent need for a shift in focus towards prevention. As someone who has endured the physical and emotional toll of cancer treatment, I can empathize with his perspective. What makes this particularly fascinating is the stark contrast between the reactive approach to cancer care and the proactive approach to prevention. From my perspective, Smith-Byrne's experience highlights the limitations of our current model and the need for a more comprehensive strategy.
One thing that immediately stands out is the underinvestment in cancer prevention. Despite knowing that up to 40% of cancers are preventable, we continue to pour most resources into treatment rather than prevention. This is a failure of imagination and a lack of confidence in what we already know we can achieve. Personally, I think this is a critical mistake. What many people don't realize is that prevention could mean people can be joyful for never needing treatment, rather than grateful to have survived.
The article highlights a litany of failures that have led to our current situation. The first is a failure of incentives. The common adage that 'prevention isn't profitable' is a convenient but inaccurate justification for underinvestment. In reality, there is a vast market for preventive medicine, as demonstrated by the success of cholesterol-lowering statins. Additionally, the business model for cancer prevention is not as uniquely difficult as it is often perceived. The modern approach is not to test drugs across vast healthy populations for decades, but to study well-defined high-risk groups, identified by genetics, lifestyle, or other factors.
A deeper issue is the belief in industry and academia that prevention is a weak and uncertain market. However, this is not true. Statins and other antihypertensives are used at a population scale to prevent cardiovascular disease, and the rapid uptake of GLP-1 medicines further supports this. What this really suggests is that when we couple long-term benefit with an immediate, tangible desirable effect, people will take prevention medicines, even where drugs have non-trivial side effects.
The final problem of incentives is political and social attention. Prevention offers delayed, diffuse benefits to a future population, while treatment offers immediate, tangible hope to an identifiable victim. Our political systems and media narratives are far more responsive to the powerful story of a patient saved by a new drug than to the abstract success of a program that prevents thousands of future, anonymous cases. This asymmetry drives attention and funding priorities.
In my view, the article makes a compelling case for a shift in focus towards cancer prevention. Genetics and emerging technologies have given us an unparalleled view into the biology of cancer risk. Since the human genome was sequenced, thousands of cancer-associated genes have been identified, yet fewer than 1% have been tested in experimental models of cancer onset. This gap represents a vast, untapped opportunity.
The article also highlights the potential for future developments in cancer prevention. There is a future where someone like me never develops cancer because the faulty APC gene is detected at birth and repaired before it ever causes harm. Similarly, gene-editing therapies for sickle cell disease show that an inherited illness can be treated by intervening at the level of its genetic cause. The next step would be to package these gene-editing tools so they are targeted to act only in the right organs.
In conclusion, Smith-Byrne's article is a call to action for a shift in focus towards cancer prevention. It highlights the limitations of our current model and the need for a more comprehensive strategy. Personally, I believe that by making prevention a priority, we can spare future generations from the devastating impact of cancer. This requires scientists to pursue biology-driven prevention with the same ambition they bring to treatment, pharmaceutical companies to recognize the viability and profitability of prevention, healthcare systems to understand the projected rise in cancer cases, and political leaders to fund cancer prevention as a priority.
